This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	VEGF; VEGF receptor 2 (KDR/Flk-1; VEGFR-2); platelet derived growth factor receptor (PDGFR); stem cell factor receptor tyrosine kinase (c-Kit; KIT; CD117)	<p><i>In vitro</i> and mouse studies identified indolinone-derived tyrosine kinase inhibitors that could help treat cancer. <i>In vitro</i>, two pyrrolo-fused, heterocycle indolinone compounds inhibited multiple kinases, including VEGFR-2, PDGFR and c-Kit, with low nanomolar IC₅₀ values. In xenograft mice with colon cancer, the inhibitors decreased tumor growth compared with vehicle control. Next steps could include testing the compounds in additional preclinical models of cancer.</p> <p>At least 27 companies have inhibitors of VEGFR-2, PDGFR or c-Kit in development stages ranging from preclinical to marketed to treat cancer.</p> <p>SciBX 3(46); doi:10.1038/scibx.2010.1380 Published online Dec. 2, 2010</p>	Patent and licensing status unavailable	<p>Cho, T.P. <i>et al. J. Med. Chem.</i>; published online Oct. 28, 2010; doi:10.1021/jm101036c</p> <p>Contact: Feng Jun, Shanghai Hengrui Pharmaceuticals Co. Ltd., Shanghai, China e-mail: fengj@shhrp.com</p>